<span item_type="fundamental" item_id="fbc28bed11ba7bc0cecd994d7f68b043" counter_id="ST/US/BFRGW" env="prod"></span><span item_type="announcement" item_id="582801064517963905" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 83.41 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.15.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -1.588 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Collaboration revenue for the three months ended September 30, 2025 was $83,413, and for the nine months ended September 30, 2025 was $116,670.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross profit for the three months ended September 30, 2025 was $15,370, and for the nine months ended September 30, 2025 was $21,892.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li><li>Loss from operations for the three months ended September 30, 2025 was - $1,569,683, and for the nine months ended September 30, 2025 was - $5,095,976.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li><li>Net loss for the three months ended September 30, 2025 was - $1,551,612, and for the nine months ended September 30, 2025 was - $5,017,894.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the nine months ended September 30, 2025 was - $4,337,270.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li><li>Net cash provided by financing activities for the nine months ended September 30, 2025 was $996,999.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The Company received net proceeds of approximately $0.3 million and $0.7 million from the sale of its common stock pursuant to the ATM Agreement during the three months ended June 30, 2025 and September 30, 2025, respectively.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The Company plans to generate revenues through strategic relationships with biopharma companies, structured as a combination of fees in cash, equity, or other consideration and intellectual property.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li><li>The Company intends to acquire rights to drugs at various stages of development and use its proprietary AI/ML technology to advance the development of such drugs, aiming to create near-term value and monetize within approximately 30 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li><li>The Company anticipates securing additional capital through revenues from licensing agreements, collaborative arrangements, selling equity securities, or entering into debt transactions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1829247/000149315225023496/form10-q.htm"></span></li></ul>

BULLFROG AI HOLDINGS INC C/WTS EXP (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 83.41 K